Peerview Clinical Pharmacology Cme/cne/cpe Audio Podcast

Go online to PeerView.com/KQX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The use of asparaginase, including E coli- and Erwinia-derived compounds, remains an important component of pediatric acute lymphoblastic leukemia (ALL) care, and its use has consistently improved survival outcomes—are you up to the challenge of developing modern regimens that ensure appropriate exposure to asparaginase? In this PeerView CME activity, based on a live “Clinical Consults” symposium at the 2022 ASPHO conference, Drs. Stuart S. Winter and Reuven Schore address the challenges of clinical decision-making with asparaginase compounds as part of pediatric ALL therapy, focusing on topics such as the management of E coli-derived asparaginase hypersensitivity or silent inactivation, preventing discontinuation/truncation, and the integration of novel Erwinia formulations when E coli-derived asparaginase discontinuation occurs. Tune in to learn how to adapt your practice to r

Go online to PeerView.com/BJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The past decade has seen new insights into the cytogenetics, molecular genetics, and disease biology of myelofibrosis (MF), including the approval of first- and second-generation JAK inhibitors and newer evidence on using JAK inhibitors in conjunction with hematopoietic stem cell transplantation (HCT). How can all of these advances be employed in an effective and safe way—and lead to improved outcomes in MF? Based on a recent PeerView Live CaseBook event, this activity will answer that question and offer an expert-led review of the latest efficacy, safety, and tolerability data associated with JAKi-based therapy and the role of HCT in patient treatment. This program also features case-based illustrations of therapy selection and sequencing designed to highlight the key take-homes of the MF lecture segments. Upon completion of this activity, participants should be better able to:

Go online to PeerView.com/GBV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS)—a serious complication arising in the aftermath of hematopoietic stem cell transplantation? In addition to life-threatening organ dysfunction in serious cases, VOD presents additional diagnostic and assessment challenges based on its varied onset time and symptomatology. PeerView’s Clinical Consults CME video will help you meet these challenges head-on through a series of case-centric lectures illustrating how modern VOD management techniques can improve outcomes in adult and pediatric patients at risk for this post-transplant complication. Throughout, our expert panelists will highlight the modern tools and evidence that can help capture VOD cases, determine the presence of organ dysfunction, and support the initiation of timely supportive care and pharmacologic treatment. Upon com

Go online to PeerView.com/AFW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Pharmacists have a central role in the management of chronic lymphocytic leukemia (CLL) and the delivery of potent targeted agents. How will new evidence influence the core tenets of pharmacy practice? In this activity, a leukemia clinical pharmacy specialist provides answers through a precise review of the newest targeted therapy standards for CLL. This program includes insights on the latest efficacy evidence and regulatory status of targeted agents in CLL, while addressing drug interactions, treatment adherence, safety considerations, dosing, and care coordination. Upon completion of this activity, participants should be better able to: Summarize the current treatment role, efficacy and safety evidence, and regulatory status of targeted therapy in CLL, including BTK, BCL-2, and PI3K inhibitors, Educate patients and clinical staff about potential drug–drug interactions, and ap

Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient’s baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better ab

Go online to PeerView.com/GUR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Gain the skills you need to adapt your current management protocols to reflect the new treatment reality in chronic lymphocytic leukemia (CLL), utilize novel combinatorial and sequential strategies, and map out the role of emerging cell-based therapies! In this activity, expert hematologist-oncologists provide expert guidance on the transformed nature of modern CLL management, the practice-changing evidence that validated targeted therapy platforms, and the science that is redefining the roles of hematopoietic stem cell transplantation and cellular therapy, including in challenging pretreated CLL settings. Upon completion of this activity, participants should be better able to: Cite current guidelines and evidence on the treatment roles of hematopoietic stem cell transplantation; BTK, PI3K, and BCL-2 inhibitors; monoclonal antibodies; and CAR-T cell therapy in the CLL setting, D

Go online to PeerView.com/EZK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Detecting molecular alterations driving the development of specific cancers and then targeting these alterations with matched therapies or combinatorial approaches is now the standard of care for many cancers. HER2 alterations have been identified as key therapeutic targets in breast, gastrointestinal, lung, and other cancers, and targeting these alterations with antibody–drug conjugates (ADCs), antibodies, more specific tyrosine kinase inhibitors, and bispecific antibodies are improving outcomes. In addition to HER2, HER3 represents an emerging target in several cancer types for which novel targeted therapies are being developed, and targeting TROP2 is showing promise as well. Given these treatment advances, biomarker testing to identify patients who may benefit the most from HER2-, HER3-, and TROP2-targeted therapies has never been more important. This activity, based on a rec

Go online to PeerView.com/KPJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent clinical developments have transformed the management of graft-versus-host disease (GVHD) and have the potential to increase access to transplants and improve post-HCT outcomes. These advances are centered on the emergence and continued research of several novel modalities, including the BTK inhibitor ibrutinib, JAK inhibitor ruxolitinib, and the T-cell co-stimulation blocking agent abatacept, as well as additional novel strategies being tested in a range of acute and chronic GVHD settings. In this activity from the 2022 Tandem meetings, our expert panelists distill the current evidence on novel therapeutics in the prevention and treatment of GVHD; throughout, they illustrate how and when to integrate novel therapeutics into care, provide guidance on how to prepare for emerging strategies, and offer practical takeaways on the changing nature of GVHD management. Upon compl

Go online to PeerView.com/DRW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Do you know the best practices for integrating chimeric antigen receptor (CAR)-T cell therapy into the management of patients with hematologic malignancies? Within the past few years, the indications for CAR-T therapy in leukemic and lymphoid malignancies have expanded significantly and now include acute lymphoblastic leukemia and multiple types of non-Hodgkin’s lymphoma. These advances, driven by the use of CD19-directed cell therapy constructs, have spurred numerous ongoing investigations of existing CAR-T therapies in additional CD19-expressing leukemias and lymphomas (eg, chronic lymphocytic leukemia, small lymphocytic lymphoma). Unfortunately, many hematology-oncology and bone marrow transplant BMT professionals have not adapted their practice to reflect the reality of cellular therapy in 2022—from the availability of new constructs with recent regulatory approvals to the m

Go online to PeerView.com/UDM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape for metastatic castration-sensitive prostate cancer (mCSPC) has evolved rapidly in recent years, and research endeavors continue to expand treatment options with significant implications for patients. In addition to the approval of multiple second-generation androgen deprivation therapies (ADTs), current clinical trials are investigating novel targeted therapies, immunotherapies, and combination approaches in different disease settings. Furthermore, when managing patients with mCSPC, clinicians must consider established, newly approved, and emerging therapies, as well as individual patient-, tumor-, and treatment-related factors. Given the wealth of new options, how do clinicians determine the best treatment course for each patient? Answers to this and other thought-provoking queries are provided in this educational activity based on a recent live sympo

Go online to PeerView.com/UTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is essential for determining the best therapeutic approach for each patient. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from targeted therapies, and the list of relevant targets and matched therapies continues to expand, including in early-stage disease settings. Unfortunately, molecular testing rates remain woefully inadequate, and even when testing is performed, many patients are not receiving optimally matched targeted therapy based on their tumor type. This PeerView educational video based on a recent live event and developed in collaboration with the LUNGevity Foundation brings leading lung cancer experts together to go beyond the basics and help navigate the increasing

Go online to PeerView.com/MWV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the recent approval of multiple novel therapeutics for patients with bladder cancer, oncology professionals have increased opportunities to improve outcomes in a variety of settings. However, not all patients are being given these promising new treatments. Management protocols often do not include the latest strategies, and clinicians often have several questions about incorporating these new agents, which include bladder-sparing options, immune checkpoint inhibitors, targeted therapies (FGFR inhibitors), and antibody-drug conjugates, into clinical practice. For instance, will the presence of immune-related adverse events (irAEs) in some patients linger after the end of therapy and limit the possible subsequent use of ADCs or FGFR inhibitors? To answer these questions, experts in bladder cancer highlight strategies for optimal care of patients in light of current evidence o

Go online to PeerView.com/ASX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Do you know the best strategies for integrating novel therapeutic approaches into the care of your patients with renal cell carcinoma (RCC)? With the rapid expansion of effective treatments, oncology nurses have more opportunities than ever before to provide support and guidance that favorably influences outcomes for their patients with advanced kidney cancer. However, research has shown that many patients are not receiving individualized, evidence-based, and guideline-concordant treatment and those patients who are receiving new therapies are not receiving appropriate nurse-led care. Join PeerView for an interprofessional case-based activity featuring two nurse professionals and an oncologist to get insight on bringing treatment advances, including immune checkpoint inhibitors and combination strategies, into clinical practice. The expert panel will provide learners with a stro

Go online to PeerView.com/YBF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF1) is an incurable and progressive genetic disorder caused by a partial or complete loss of function of the NF1 tumor suppressor gene, resulting in elevated RAS-mitogen-activated protein kinase (RAS/MAPK) pathway signaling and the potential development of subsequent NF1-associated tumors. Given current breakthroughs, including the emergence of MEK inhibitors, the ongoing challenge is how to effectively employ modern therapeutics in the management of patients with NF1 tumors, particularly pediatric patients. This case-based video discussion, based on a PeerView live “Seminars & Practicum” CME event, will offer an expert-guided review of the challenges inherent to the management of NF1-associated tumors and provide practical guidance on state-of-the-art solutions and the role that MEK-targeting agents can play in patient management. Upon completion

Go online to PeerView.com/XNU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on refractory ascites and esophageal variceal hemorrhage (EVH) discusses evidence-based strategies to improve patient outcomes. Upon completion of this activity, participants should be better able to: Summarize the prevalence, pathophysiology, and consequences of decompensated cirrhosis and portal hypertension (eg, refractory ascites and EVH), Evaluate the latest evidence for current and emerging approaches to managing patients with refractory ascites and EVH.

Go online to PeerView.com/QWZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for the current clinical challenges of CLL—including in areas where nurse professionals can have a decisive influence on patient education and the safe delivery of care? This “Clinical Consults” activity, developed in collaboration with the CLL Society, represents a resource for developing modern management strategies in a changing and complicated therapeutic landscape. Throughout, PeerView’s expert speakers present nurse-to-nurse, case-based education and share clinical tools designed to facilitate the effective use of innovative therapeutics in chronic lymphocytic leukemia (CLL) across multiple treatment settings, with the ultimate goal of enhancing patient outcomes. Upon completion of this activity, participants should be better able to: Cite the clinical signs of symptomatic disease, relevant prognostic factors, patient- and disease-related features, and cli

Go online to PeerView.com/CCT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in dermatology discuss the role of the JAK/STAT pathway in psoriasis, as well as treatment with novel kinase inhibitors for the management of patients with psoriasis. Upon completion of this activity, participants should be better able to: Describe and differentiate targeting of the TYK2, JAK1, JAK2, and JAK3 kinases and the correlation to emerging therapies for the treatment of moderate to severe psoriasis, Summarize recent efficacy and safety data for current and emerging therapies for the treatment of moderate to severe psoriasis, Recommend treatment for patients with moderate to severe psoriasis according to the latest guidelines and clinical evidence, particularly as emerging therapies become available.

Go online to PeerView.com/VSV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent transformation of the bladder cancer therapeutic landscape includes the PD-1/PD-L1–targeting immune checkpoint inhibitors for advanced/metastatic bladder cancer, erdafitinib for FGFR mutation–positive bladder tumors, and the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan in the post–immune checkpoint inhibitor setting. Utilizing these agents in localized disease settings has led to the emergence of novel bladder-sparing and perioperative approaches, including the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. This PeerView activity, developed in collaboration with the Bladder Cancer Advocacy Network, will guide le

Go online to PeerView.com/GWF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to the early-stage setting and transforming the multimodal management of resectable stage I-III NSCLC. Remarkable data have emerged from several immunotherapy trials in perioperative settings and FDA has granted new regulatory approvals for both neoadjuvant and adjuvant immunotherapy regimens, effectively establishing new standards of care in early-stage NSCLC. Still, many questions remain on how to transition these exciting advances to practice and improved patient outcomes in real-world setting. What are the pros/cons of neoadjuvant versus adjuvant immunotherapy, and how should the best approach be determined for each patient? What is the optimal timing and duration of therapy, and how should responses be assessed? What adverse events should be anticipated, and are perioperative complications hig

Go online to PeerView.com/PFM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) represent a unique class of anticancer therapies showing promise in a broad range of solid tumors. ADCs targeting HER2 and TROP2 have already garnered regulatory approvals in some cancer types, with more trials under way, and therapies against other new targets, including HER3, are being explored as well. This PeerView educational activity based on a recent live symposium focuses on the implications of recent advances with ADCs and provides guidance for oncology nurses and other key members of the cancer care team on their clinical integration in a new era of targeted therapy across solid tumors. Upon completion of this activity, participants should be better able to: Describe the properties, mechanisms of action, latest clinical evidence, and current and potential clinical roles of validated and emerging HER2-, HER3-, and TROP2-targeted antibody-